The global discourse power of new drugs has long been anchored in San Francisco. Nowadays, when Chinese pipelines and BD transactions dominate half of the world, the world urgently needs a strategic hub that is stationed in the East and connects the globe.

CPIC 2026， That's the answer.

From July 22nd to 24th, the Shanghai National Convention and Exhibition Center - this "four leaf clover" that has witnessed countless miracles - will create the ultimate home for the Chinese version of JPM under the name of "National New Drug". This is not a one-way 'internationalization', but the 'presence' of global forces.

✔  Global gathering, crossing mountains and seas

Core forces from four continents and fifteen countries gather: all five European countries have arrived, Lilly AZ、 Led by SVP of Bayer and Roche, the four multinational giants; Seven regions in Asia never fall, with heavyweight players such as Astellas, South Korean Biotech, Singapore, and Saudi Arabia entering the market; South American powers such as Brazil also broke the deadlock strongly.

✔ Penetrating the entire chain, shattering the dilemma

60+sessions, 600+topics, 800 speakers, and 40 technology tracks directly targeting global pain points. From BD going global, NewCo model to cross-border BD and mergers and acquisitions, from "selling seedlings" to "selling harvest", pricing power is discussed on site! The special sessions of China US, China Europe, China Japan, and "BRICS" allow global capital to gather here and initiate borderless business dialogue.

✔ The decision-making level is present, and all dimensions are in place

Academicians Xie Xiaoliang, Chen Kaixian and others lead the academic highland; Leading figures from industries such as Baekje, Kangfang, Baili Tianheng, and WuXi Biologics were all present; Huawei, Jingtai, Yingsi Intelligence and other AI new forces bring cutting-edge practices; Junlian, Ernst&Young, Fangda Law Firm and other capital full chain platforms; The top clinical PI authority is in charge.

When innovative elements intersect in the same field, Chinese new drugs will complete a closed loop from technical validation to commercialization on their own turf.

CPIC 2026 does not discuss whether China can innovate, but only answers core questions of common concern at home and abroad:

▪ How can China's efficiency accelerate global innovation?

▪ How can global capital seize the opportunities in China?

From July 22nd to 24th, at the Shanghai National Convention and Exhibition Center.

Let us witness together the arrival of a new era of new drugs in China!

Guiding Institutions：Shanghai Biopharmaceutical Technology Industry Promotion Center、Shanghai Center for Innovative Drug R&D、Shanghai Global Health Innovation Research Institute

Organizing Unit：Tonacea

Strategic Partners：School of Biotechnology, Fudan University、GPHL、WuXi AppTec、WuXi Biologics、Tofflon、Huawei Pharmaceutical BU、Ernst & Young、Fangda Partners、Legend Capital、China Chamber of Commerce for Import and Export of Medicines and Health Products、NECC(Shanghai)

25% off for the last 10 days! 

Register quickly
 

Meeting Agenda